In addition, in DU145 xenografts we observed that Apo2L/TRAIL, lexatumumab, sorafenib and sorafenib +Apo2L/TRAIL delayed tumor growth (Figure 5A). This evidence concerns the gene TNFSF10 and neoplasm.